Amyl Therapeutics
0758.775.372 · rovalta.com · 25/09/2026
ACTIVE
Amyl Therapeutics
Financial year 2025 · Closed on 31/12/2025
Net result-2 M €+17,3 %over 1 year
Gross margin-365,9 k €+58,1 %over 1 year
Equity3,5 M €-36,2 %over 1 year
Workforce6,8 ETP+47,8 %over 1 year
Overview
Identity
Source · BCE/KBOAmyl Therapeutics is a Private limited company incorporated in 2020. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Liège. It employs on average 6,8 ETP workers (FTE).
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0758.775.372
- Incorporation
- 26/11/2020
- Legal form
- Private limited company
- Registered office
- Boulevard de Patience et Beaujonc 3
4000 Liège · WallonieSee on map - Contributed capital
- 5 971 289,80 €
- Latest accounts
- 31/12/2025
- Average workforce
- 6,8 ETP
Activities (NACE)
Joint committees (2)
- 200
- 200000
Signals
Solid equityPositive cashflowHealthy social debts
Financials
Source · NBB, 6 filingsTrend over 5 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | -365,9 k € | +58.1% | -872,4 k € | -29.4% | -674,4 k € | +19.8% | -840,6 k € | +3.9% | -875,1 k € |
| EBITDA | -1 M € | +23.8% | -1,4 M € | -15.0% | -1,2 M € | -11.9% | -1,1 M € | -20.1% | -888,7 k € |
| Operating result | -3,9 M € | -0.4% | -3,9 M € | -20.5% | -3,2 M € | -38.7% | -2,3 M € | -91.6% | -1,2 M € |
| Net result | -2 M € | +17.3% | -2,4 M € | -42.5% | -1,7 M € | -20.8% | -1,4 M € | -41.6% | -999,7 k € |
| Balance sheet | |||||||||
| Equity | 3,5 M € | -36.2% | 5,6 M € | -30.5% | 8 M € | +28.8% | 6,2 M € | -18.6% | 7,6 M € |
| Total assets | 7 M € | -16.3% | 8,4 M € | -6.5% | 9 M € | +33.7% | 6,7 M € | -23.2% | 8,7 M € |
| Cash | 616,7 k € | -73.0% | 2,3 M € | -26.1% | 3,1 M € | +107% | 1,5 M € | -58.7% | 3,6 M € |
| Debts | 3,3 M € | +23.6% | 2,7 M € | +178% | 965 k € | +95.4% | 493,9 k € | -54.9% | 1,1 M € |
| Other | |||||||||
| Workforce | 6,8 ETP | +47.8% | 4,6 ETP | – | – | – | |||
Valuation
Indicative valuation
As an indication, this company is worth
between 2,5 M€ and 5 M€
See the valuationBoard of directors
Source · NBB, accounts to 31/12/20256 active · 13 ended
Active mandates
Christopher MAC NAUGHTON
ActiveKenneth BUCKFIRE
ActiveMERIEUX PARTICIPATIONS SAS
ActiveActive
Active
Ended mandates
Other companies at this address
Boulevard de Patience et Beaujonc 3 4000 Liège| Company | CBE no. |
|---|---|
Abscint● Active | 0749.828.410 |
AMPACIMON● Active | 0827.990.317 |
BECARV● Bankrupt | 0840.777.885 |
BE.SPINE● Active | 1013.110.857 |
CEFALY Technology● Active | 0870.578.661 |
DERMAX● Active | 0667.730.677 |
DIANOSIC● Active | 1034.558.646 |
DW Cefaly Holding● Active | 0725.837.241 |
| 1023.778.481 | |
EXO Biologics● Active | 0732.982.379 |
ExoXpert● Active | 1003.807.666 |
Hirundo Biosciences● Active | 0681.855.065 |
HolyFox Invest● Active | 1010.693.181 |
Hyloris● Active | 0669.738.676 |
Hyloris Developments● Active | 0542.737.368 |
Hyloris Pharmaceuticals● Active | 0674.494.151 |
Hyloris Therapeutics● Active | 1025.029.385 |
LEGIAPARK● Active | 0728.589.170 |
MAN & SCIENCE● Active | 0837.403.770 |
ONCORADIOMICS● Active | 0662.719.440 |
Financials
Full financial information
Source · NBB| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Micro model | Micro model | Micro model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/11/2020 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 14 months |
| Filing date | 22/07/2026 | 02/07/2025 | 05/06/2024 | 03/07/2023 | 03/07/2023 |
| General meeting | 16/06/2026 | 13/06/2025 | 04/06/2024 | 21/06/2023 | 16/05/2023 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for 7 daysAnnual accounts filings
Source · NBB, 6 filings| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2025 | 16/06/2026 | 22/07/2026 | French | |
| Abridged model | 31/12/2024 | 13/06/2025 | 02/07/2025 | French | |
| Micro model | 31/12/2023 | 04/06/2024 | 05/06/2024 | French | |
| Micro model | 31/12/2022 | 21/06/2023 | 03/07/2023 | French | |
| Micro modelCorrection | 31/12/2021 | 16/05/2023 | 03/07/2023 | French | |
| Micro model | 31/12/2021 | 07/06/2022 | 29/08/2022 | French |
Valuation
Indicative valuation
Order of magnitude
As an indication, this company is worth
between 2,5 M€ and 5 M€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20256 active · 13 ended
Active mandates
Christopher MAC NAUGHTON
ActiveKenneth BUCKFIRE
ActiveMERIEUX PARTICIPATIONS SAS
ActiveActive
Active
Ended mandates
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Belgian Official Gazette publications
Source · Belgian Official Gazette- Mandates22/07/2026DEMISSIONS, NOMINATIONS
- Capital / shares22/12/2025CAPITAL, ACTIONS
- Capital / shares04/02/2025CAPITAL, ACTIONS - DIVERS
- Registered office14/05/2024SIEGE SOCIAL
- Capital / shares12/02/2024DIVERS - CAPITAL, ACTIONS
- Capital / shares12/09/2023CAPITAL, ACTIONS
- Capital / shares12/04/2023CAPITAL, ACTIONS
- Mandates04/04/2023DEMISSIONS, NOMINATIONS
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025-2 M €↑
- 2024Annual accounts 2024-2,4 M €↓
- 2023Annual accounts 2023-1,7 M €↓
- 2022Annual accounts 2022-1,4 M €↓
- 2021Annual accounts 2021-999,7 k €
- 26/11/2020IncorporationPrivate limited company